Detalles de la búsqueda
1.
Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
Int J Clin Pract
; 2024: 8585035, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38375028
2.
Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Technol Cancer Res Treat
; 23: 15330338241227055, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38258375
3.
Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection.
Oncol Res Treat
; 45(6): 366-374, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35231913
4.
Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study.
Front Oncol
; 12: 1036906, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36698393
5.
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy.
Front Oncol
; 11: 692703, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34322390
6.
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
J Thorac Dis
; 13(5): 2959-2967, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34164187
Resultados
1 -
6
de 6
1
Próxima >
>>